Ascletis Pharma Inc.

SEHK:1672 Stock Report

Market Cap: HK$13.6b

Ascletis Pharma Future Growth

Future criteria checks 2/6

Ascletis Pharma's earnings are forecast to decline at 5.4% per annum while its annual revenue is expected to grow at 57.8% per year. EPS is expected to decline by 6.7% per annum. Return on equity is forecast to be -33.6% in 3 years.

Key information

-5.4%

Earnings growth rate

-6.66%

EPS growth rate

Biotechs earnings growth39.6%
Revenue growth rate57.8%
Future return on equity-33.59%
Analyst coverage

Low

Last updated26 Oct 2025

Recent future growth updates

Recent updates

We're Hopeful That Ascletis Pharma (HKG:1672) Will Use Its Cash Wisely

Jun 17
We're Hopeful That Ascletis Pharma (HKG:1672) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Ascletis Pharma's (HKG:1672) Cash Burn Situation

Feb 19
Here's Why We're Not Too Worried About Ascletis Pharma's (HKG:1672) Cash Burn Situation

Is Ascletis Pharma (HKG:1672) In A Good Position To Deliver On Growth Plans?

Oct 07
Is Ascletis Pharma (HKG:1672) In A Good Position To Deliver On Growth Plans?

We're Not Very Worried About Ascletis Pharma's (HKG:1672) Cash Burn Rate

Dec 19
We're Not Very Worried About Ascletis Pharma's (HKG:1672) Cash Burn Rate

We're Hopeful That Ascletis Pharma (HKG:1672) Will Use Its Cash Wisely

Aug 23
We're Hopeful That Ascletis Pharma (HKG:1672) Will Use Its Cash Wisely

What You Need To Know About The Ascletis Pharma Inc. (HKG:1672) Analyst Downgrade Today

Nov 03
What You Need To Know About The Ascletis Pharma Inc. (HKG:1672) Analyst Downgrade Today

Companies Like Ascletis Pharma (HKG:1672) Can Afford To Invest In Growth

Oct 13
Companies Like Ascletis Pharma (HKG:1672) Can Afford To Invest In Growth

Need To Know: Analysts Just Made A Substantial Cut To Their Ascletis Pharma Inc. (HKG:1672) Estimates

Aug 24
Need To Know: Analysts Just Made A Substantial Cut To Their Ascletis Pharma Inc. (HKG:1672) Estimates

Here's Why We're Not Too Worried About Ascletis Pharma's (HKG:1672) Cash Burn Situation

May 19
Here's Why We're Not Too Worried About Ascletis Pharma's (HKG:1672) Cash Burn Situation

Earnings and Revenue Growth Forecasts

SEHK:1672 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202754-383N/A-3745
12/31/2026259-137N/A-4135
12/31/20251-369N/A-1045
6/30/20252-259-313-311N/A
3/31/20252-280-328-326N/A
12/31/20241-301-344-342N/A
9/30/20246-280-361-350N/A
6/30/202410-258-380-359N/A
3/31/202433-202-311-292N/A
12/31/202357-145-243-224N/A
9/30/202359-194-208-197N/A
6/30/202362-243-173-171N/A
3/31/202358-279-195-187N/A
12/31/202254-315-217-202N/A
9/30/202266-246-198-182N/A
6/30/202279-176-179-161N/A
3/31/202278-188-167-154N/A
12/31/202177-199-154-147N/A
9/30/202158-234-172-150N/A
6/30/202140-269-190-153N/A
3/31/202137-239-157-119N/A
12/31/202035-209-124-85N/A
9/30/202082-155-86-56N/A
6/30/2020130-100-47-28N/A
3/31/2020152-98-75-51N/A
12/31/2019173-96-103-74N/A
9/30/2019150-92-130-91N/A
6/30/2019127-89-157-107N/A
3/31/2019153-43N/A-83N/A
12/31/2018166-7N/A-97N/A
9/30/2018154-5N/A-134N/A
6/30/2018142-2N/A-171N/A
3/31/201891-40N/A-210N/A
12/31/201753-54N/A-198N/A
12/31/201633-27N/A-12N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 1672 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 1672 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 1672 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 1672's revenue (57.8% per year) is forecast to grow faster than the Hong Kong market (8.5% per year).

High Growth Revenue: 1672's revenue (57.8% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 1672 is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/16 06:16
End of Day Share Price 2025/11/14 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Ascletis Pharma Inc. is covered by 10 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ling ZhangChina Merchants Securities (HK) Co., Ltd
Wangbin ZhouCitigroup Inc
Ming JiangEast Asia Qianhai Securities Co., Ltd